Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS
26 ledna, 2021 8:53 pmAuthor(s): R. Advani, N. Bartlett, S. Smith, M. Roschewski, L. Popplewell, et al. EHA Library. Roschewski M. Jun 15, 2019;...
PEGCRISANTASPASE AND VENETOCLAX COMBINATION IS HIGHLY EFFECTIVE AGAINST ACUTE MYELOID LEUKEMIA (AML), MECHANISTICALLY DRIVEN SYNERGISM BETWEEN GLUTAMINE DEPLETION AND BCL-2 INHIBITION
26 ledna, 2021 8:53 pmAuthor(s): A. Emadi1, R. Gartenhaus, B. Bhandary, H. Kaizer, E. Chang, et al. EHA Library. Emadi A. Jun 15, 2019;...
THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML
26 ledna, 2021 8:53 pmAuhor(s): K. Morita, F. Wang, K. Jahn, Y. Yan, R. Durruthy-Durruthy, et al. EHA Library. Morita K. Jun 15, 2019;...
DECIPHERING THE ROLE OF RUNX1 ISOFORMS IN THE DEVELOPMENT OF TRANSIENT ABNORMAL MYELOPOIESIS
26 ledna, 2021 8:53 pmAuthor(s): S. Gialesaki, M. Labuhn, D. Brauer-Hartmann, S. Matzk, F.-J. Struwe, et al. EHA Library. Gialesaki S. Jun 14, 2019;267347;...
Co je nového v léčbě AML?
26 ledna, 2021 8:53 pmVe dnech 13.–16. června 2019 se v Amsterdamu konal 24. kongres Evropské hematologické společnosti, který přinesl komplexní přehled novinek z oblasti onkologické a neonkologické...
BLINATUMOMAB FOR MINIMAL RESIDUAL DISEASE (MRD) IN ADULTS WITH BCELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCPALL): MEDIAN OVERALL SURVIVAL (OS) NOT REACHED AT 5 YEARS FOR COMPLETE MRD RESPONDERS
26 ledna, 2021 8:53 pmAuthor(s): Nicola Goekbuget, Hervé Dombret, Gerhard Zugmaier, Massimiliano Bonifacio, Carlos Graux, et al. EHA Library. Goekbuget N. Jun 16, 2019;...
REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM
26 ledna, 2021 8:53 pmAuthor(s): C. Thieblemont, S. Legouill, R. Di Blasi, G. Cartron, F. Morschhauser, et al. EHA Library. Thieblemont C. Jun 16,...
PET AFTER 2 CYCLES OF ABVD IN PATIENTS WITH EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA TREATED WITHIN THE PHASE 3 GHSG HD16 STUDY
26 ledna, 2021 8:53 pmAuthor(s): M. Fuchs, H. Goergen, C. Kobe, H. Eich, C. Baues, et al. EHA Library. Fuchs M. Jun 15, 2019;...
FIVE-YEAR FOLLOW-UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
26 ledna, 2021 8:53 pmAuthor(s) A. Tedeschi, J. Burger, P. M. Barr, T. Robak, C. Owen, et al. EHA Library. Tedeschi A. Jun 14,...
THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL
26 ledna, 2021 8:53 pmAuthor(s): E. Tiacci, L. De Carolis, E. Simonetti, F. Zaja, M. Capponi, et al. EHA Library. Tiacci E. Jun 14,...